The current state of molecular profiling in gastrointestinal malignancies. [Review]

MedStar author(s):
Citation: Biology Direct [Electronic Resource]. 17(1):15, 2022 06 06.PMID: 35668531Institution: MedStar Washington Hospital CenterDepartment: Hematology & Oncology Fellowship | Hematology & Oncology Fellowship | Hematology/Oncology Fellowship | MedStar Georgetown University Hospital/MedStar Washington Hospital CenterForm of publication: Journal ArticleMedline article type(s): Journal Article | ReviewSubject headings: *Gastrointestinal Neoplasms | *Precision Medicine | Biomarkers, Tumor/ge [Genetics] | Gastrointestinal Neoplasms/di [Diagnosis] | Gastrointestinal Neoplasms/ge [Genetics] | High-Throughput Nucleotide Sequencing | Humans | Liquid Biopsy | MutationYear: 2022Local holdings: Available online through MWHC library: 2006 - presentISSN:
  • 1745-6150
Name of journal: Biology directAbstract: This is a review of the current state of molecular profiling in gastrointestinal (GI) cancers and what to expect from this evolving field in the future. Individualized medicine is moving from broad panel testing of numerous genes or gene products in tumor biopsy samples, identifying biomarkers of prognosis and treatment response, to relatively noninvasive liquid biopsy assays, building on what we have learned in our tumor analysis and growing into its own evolving predictive and prognostic subspecialty. Hence, the field of GI precision oncology is exploding, and this review endeavors to summarize where we are now in preparation for the journey ahead. Copyright © 2022. The Author(s).All authors: Alqahtani AZ, Hameed R, Hartley ML, He AR, Kulasekaran M, Marshall JL, Mukherji R, Noel MS, Weinberg BA, Yin CFiscal year: FY2022Digital Object Identifier: Date added to catalog: 2022-07-06
Holdings
Item type Current library Collection Call number Status Date due Barcode
Journal Article MedStar Authors Catalog Article 35668531 Available 35668531

Available online through MWHC library: 2006 - present

This is a review of the current state of molecular profiling in gastrointestinal (GI) cancers and what to expect from this evolving field in the future. Individualized medicine is moving from broad panel testing of numerous genes or gene products in tumor biopsy samples, identifying biomarkers of prognosis and treatment response, to relatively noninvasive liquid biopsy assays, building on what we have learned in our tumor analysis and growing into its own evolving predictive and prognostic subspecialty. Hence, the field of GI precision oncology is exploding, and this review endeavors to summarize where we are now in preparation for the journey ahead. Copyright © 2022. The Author(s).

English

Powered by Koha